Patents Assigned to SuperGen, Inc.
-
PHARMACEUTICAL FORMULATIONS COMPRISING SALTS OF A PROTEIN KINASE INHIBITOR AND METHODS OF USING SAME
Publication number: 20080226747Abstract: The present invention relates to pharmaceutical formulations comprising the protein kinase inhibitor, MP470, and methods of using same in treating conditions involving undesirable cell proliferation, such as cancer.Type: ApplicationFiled: March 3, 2008Publication date: September 18, 2008Applicant: SUPERGEN, INC.Inventors: David J. Bearss, Rajashree Joshi-Hangal, Xiao-Hui Liu, Pasit Phiasivongsa, Sanjeev G. Redkar, Hariprasad Vankayalapati -
Publication number: 20080214558Abstract: Pyrimidine-2,4-diamines derivatives having activity as JAK2 kinase inhibitors are disclosed, as well as pharmaceutical compositions and methods for using the same in the treatment of cancer and other JAK2 kinase-associated conditions.Type: ApplicationFiled: February 29, 2008Publication date: September 4, 2008Applicant: SUPERGEN, INC.Inventors: Hariprasad Vankayalapati, Xiao-Hui Liu, David J. Bearss
-
Publication number: 20080207632Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer, such as Aurora kinase-expressing cancers and Axl kinase-expressing cancers. Compounds of the invention have the following structure: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Z, L2 and w are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.Type: ApplicationFiled: October 31, 2007Publication date: August 28, 2008Applicant: SUPERGEN, INC.Inventors: David J. Bearss, Cory L. Grand, Xiao-Hui Liu, Hariprasad Vankayalapati
-
Publication number: 20080175814Abstract: Quinoline derivatives, particularly 4-anilinoquinoline derivatives, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders.Type: ApplicationFiled: October 12, 2007Publication date: July 24, 2008Applicant: SUPERGEN, INC.Inventors: Pasit Phiasivongsa, Sanjeev Redkar, Swarna Gamage, Darby Brooke, William Denny, David J. Bearss, Hariprasad Vankayalapati
-
Publication number: 20080051414Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.Type: ApplicationFiled: March 1, 2007Publication date: February 28, 2008Applicants: Arizona Board of Regents on Behalf of The University of Arizona, SuperGen,IncInventors: Laurence Hurley, Daruka Mahadevan, Haiyong Han, David Bearss, Hariprasad Vankayalapati, Sridevi Bashyam, Ruben Munoz, Steven Warner, Kimiko Della Croce, Daniel Von Hoff, Cory Grand, James Welsh
-
Patent number: 7326712Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.Type: GrantFiled: October 14, 2004Date of Patent: February 5, 2008Assignees: Arizona Board of Regents on behalf of The University of Arizona, Supergen, Inc.Inventors: Laurence H. Hurley, Daruka Mahadevan, David J. Bearss, Hariprasad Vankayalapati, Sridevi Bashyam, Steven L. Warner
-
Patent number: 7276228Abstract: Methods are provided for treating hematological disorders by inhibition of DNA hypomethylation and histone deacetylase. Such disorders include, for example, acute promyelocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, myelodysplastic syndromes, and sickle cell anemia. The methods comprise: administering to a patient suffering from the disease a therapeutically effective amount of a DNA methylation inhibitor such as a cysteine analog such as decitabine, in combination with an effective amount of histone deacetylase inhibitor such as hydroxamic acid, cyclic peptide, benzamide, butyrate, and depudecin.Type: GrantFiled: March 15, 2005Date of Patent: October 2, 2007Assignee: SuperGen, Inc.Inventor: Jorge F. DiMartino
-
Patent number: 7250416Abstract: Compounds and compositions of azacytosine analogs and derivatives are provided. In one aspect of the invention, analogs or derivatives of decitabine and azacitidine are provided with modification at the 4- and 6-position of the triazine ring, at the 1?–6? position of the ribose ring, or combinations thereof. Methods of synthesizing and manufacturing these analogs and derivatives are also provided. These compounds can be formulated into pharmaceutical compositions that can be used for treating any disease that is sensitive to the treatment with decitabine or azacitidine, such as hematological disorders and cancer.Type: GrantFiled: March 11, 2005Date of Patent: July 31, 2007Assignee: SuperGen, Inc.Inventors: Pasit Phiasivongsa, Sanjeev Redkar
-
Patent number: 7144873Abstract: Pharmaceutical formulations, kits and vessels are provided for delivering decitabine to a patient suffering from a disease in need of treatment with decitabine. The pharmaceutical formulation comprises decitabine solvated in a non-aqueous solvent that comprises glycerin, propylene glycol, polyethylene glycol, or combinations. Such formulations are more chemically stable than conventional liquid formulations of decitabine containing more than 40% water in volume. The pharmaceutical formulations can be used for any disease that is sensitive to the treatment with decitabine, such as hematological disorders and cancer.Type: GrantFiled: July 13, 2004Date of Patent: December 5, 2006Assignee: SuperGen, Inc.Inventors: Rajashree Joshi-Hangal, Xichen Zhang, Stephanie Gong, Sanjeev Redkar, Ashok Y. Gore
-
Publication number: 20060264439Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein ring moiety A, R1, R2, R3, R4, R5, R6, R7, R8 and X are as defined herein. Also disclosed are compositions comprising such compounds and methods of using same.Type: ApplicationFiled: May 17, 2006Publication date: November 23, 2006Applicant: SuperGen, Inc.Inventors: David Bearss, Hariprasad Vankayalapati, Cory Grand
-
Patent number: 7135464Abstract: Pharmaceutical formulations, kits and vessels are provided for delivering decitabine to a patient suffering from a disease in need of treatment with decitabine. The pharmaceutical formulation comprises decitabine solvated in a non-aqueous solvent that comprises glycerin, propylene glycol, polyethylene glycol, or combinations. Such formulations are more chemically stable than conventional liquid formulations of decitabine containing more than 40% water in volume. The pharmaceutical formulations can be used for any disease that is sensitive to the treatment with decitabine, such as hematological disorders and cancer.Type: GrantFiled: July 13, 2004Date of Patent: November 14, 2006Assignee: SuperGen, Inc.Inventors: Rajashree Joshi-Hangal, Xichen Zhang, Stephanie Gong, Sanjeev Redkar, Ashok Y. Gore
-
Patent number: 7071202Abstract: A polymorphic form of 9-nitrocamptothecin is provided, the polymorph being characterizable as having, by differential scanning calorimetry, no observable endotherm and an exotherm at between 273.6 and 275.6° C., and a solution NMR spectrum with multiplets at 1.7 and 3.7 ppm shifts.Type: GrantFiled: February 21, 2002Date of Patent: July 4, 2006Assignee: SuperGen, Inc.Inventors: Sanjeev Redkar, Ashok Gore
-
Patent number: 7060290Abstract: Disclosed are compounds of general formula (I) that function as prodrugs, thereby increasing bioavailabilities of the linked therapeutic agents, wherein the LINKER is (i) substituted or unsubstituted alkyl, (ii) substituted or unsubstituted alkenyl, (iii) substituted or unsubstituted alkanoyl, (iv) substituted or unsubstituted alkenoyl wherein the double bond is cis, and (v) (ortho or para) carbonyl-substituted aryl; and wherein the subtituent is each an independent group or linked together thereby forming a ring; and wherein X is one or more substituted or unsubstituted group containing one or more O, N, or S atom and wherein the substituent is each an independent group or linked together thereby forming a ring; and wherein the therapeutic agent is an alcohol-containing water-insoluble steroids or another alcohol containing compounds and methods to prepare such compounds.Type: GrantFiled: February 16, 2000Date of Patent: June 13, 2006Assignee: Supergen, Inc.Inventors: Bruce H. Morimoto, Peter L. Barker
-
Patent number: 7049322Abstract: A polymorphic form of 9-nitrocamptothecin is provided, the polymorph being characterizable as having, by differential scanning calorimetry, an endotherm at between 273.9 to 275.9° C., and an exotherm at between 279.3 and 281.3° C.Type: GrantFiled: February 21, 2002Date of Patent: May 23, 2006Assignee: SuperGen, Inc.Inventors: Sanjeev Redkar, Ashok Gore
-
Patent number: 7037900Abstract: Compositions and methods are provided for prevention and clinical treatment of various forms of graft-versus-host disease (GVHD) by using inhibitors of adenosine deaminase (ADA). In particular, various formulations and dosing regimens of ADA inhibitors such as pentostatin are provided for the treatment of humans in vivo as well as for ex vivo conditioning of organ transplants in order to specifically suppress T-lymphocyte mediated immune responses while minimizing systemic toxicity of the drug.Type: GrantFiled: October 12, 2001Date of Patent: May 2, 2006Assignee: SuperGen, Inc.Inventors: Jorge DiMartino, John Tippett Nelson
-
Publication number: 20060063735Abstract: The present invention relates to salts of 5-azacytidine as well as methods for synthesizing the salts described herein. Pharmaceutical compositions and methods of using the 5-azacytidine salts are also provided, including methods of administering the salts or pharmaceutical compositions thereof to treat conditions, such as cancer and hematological disorders.Type: ApplicationFiled: September 17, 2004Publication date: March 23, 2006Applicant: SuperGen, Inc.Inventors: Sanjeev Redkar, Pasit Phiasivongsa
-
Patent number: 6998391Abstract: Methods are provided for treating diseases associated with abnormal activity of kinases. The method comprises: administering a DNA methylation inhibitor to the patient in therapeutically effective amount; and administering a kinase inhibitor to the patient in therapeutically effective amount, such that the in vivo activity of the kinase is reduced relative to that prior to the treatment.Type: GrantFiled: July 26, 2002Date of Patent: February 14, 2006Assignee: SuperGen.Inc.Inventors: John Lyons, Joseph Rubinfeld
-
Publication number: 20060014949Abstract: Pharmaceutical compositions and methods for treatment of neoplastic conditions using polymorphs of decitabine are provided. Also provided are methods for manufacturing and administering such pharmaceutical compositions.Type: ApplicationFiled: July 13, 2004Publication date: January 19, 2006Applicant: SuperGen Inc.Inventors: Sanjeev Redkar, Rajashree Joshi-Hangal
-
Patent number: 6982253Abstract: Pharmaceutical formulations, kits and vessels are provided for delivering decitabine to a patient suffering from a disease in need of treatment with decitabine. The pharmaceutical formulation comprises decitabine solvated in a non-aqueous solvent that comprises glycerin, propylene glycol, polyethylene glycol, or combinations. Such formulations are more chemically stable than conventional liquid formulations of decitabine containing more than 40% water in volume. The pharmaceutical formulations can be used for any disease that is sensitive to the treatment with decitabine, such as hematological disorders and cancer.Type: GrantFiled: June 5, 2002Date of Patent: January 3, 2006Assignee: SuperGen, Inc.Inventors: Rajashree Joshi-Hangal, Xichen Zhang, Stephanie Gong, Sanjeev Redkar, Ashok Y. Gore
-
Patent number: 6977247Abstract: A method is provided for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation, the method comprising: administering to the patient a 20(S)-camptothecin for a period of time during which a pyrimidine base analog is not being administered to the patient; and administering a pyrimidine base analog to the patient.Type: GrantFiled: February 21, 2002Date of Patent: December 20, 2005Assignee: SuperGen, Inc.Inventors: Joseph Rubinfeld, Karl L. Mettinger, John Lyons, Lawrence A. Romel